Bristol Boosts ImClone Funding To Accelerate Erbitux Development
This article was originally published in The Pink Sheet Daily
Executive Summary
Bristol will invest an additional “several hundred million dollars” toward Erbitux late-stage clinical trials in brain, breast, bladder, esophageal, gastric and lung cancers.